A phase II trial comparing dual MAPK pathway inhibition by combining BRAF and MEK
inhibitors with BRAF inhibition alone showed increased progression-free survival and …

The treatment of melanoma has been revolutionized over the past decade with the
development of effective molecular and immune targeted therapies. The great majority of …

Treatment of advanced melanoma has undergone a paradigm shift over the last 10–15
years. The frustrating results of studies on medical treatment ten years ago have been …

New drugs targeting the mitogen-activated protein kinase (MAPK) pathway have generated
striking clinical response in melanoma therapy. From the discovery of BRAF mutation in …

Introduction: Selective inhibition of the MAPK pathway with either BRAF or MEK inhibition
has emerged as a key component for the treatment of BRAF-mutant metastatic melanoma …

The development of novel treatments that selectively inhibit the RAS-RAF-MAPK pathway
represents a milestone in the history of melanoma treatment. BRAF mutations occur in …

Opinion statement Melanoma is the most aggressive of the cutaneous malignancies,
causing more than 9,000 deaths in the past year in the United States. Historically, systemic …

Combination therapy of melanoma using kinase inhibitors : Current Opinion in Oncology
Combination therapy of melanoma using kinase inhibitors : Current Opinion in Oncology Log …

Introduction: Breakthroughs in targeted therapy have significantly improved outcomes for
many patients with advanced melanoma, including those with BRAFV600 mutant disease …

Selective inhibition of the mitogen activated protein kinase (MAPK) pathway with either
BRAF or MEK inhibition has emerged as the key component for the treatment of BRAF …